Headed by CEO Ann Gidner, with a global career spanning 25 years and extensive experience in implementing new business models and partnerships, Ziccum’s Management Team are experts in biologic drug development and formulation.
Ann Gidner, CEO
Appointed: May 9, 2022.
Qualifications: MSc Chemical Engineering Bioprocessing, Lund University and École Nationale Supérieure d’Ingénieurs de Génie Chimique de Toulouse. MBA, Lund University. Diplôme de Francais, Étoile, Paris.
Experience: Ann has 25+ years of experience from Life Science management internationally, with a significant track record in strategic development, focused leadship, deal making and sales growth. Generating steep growth in leading, international Pharma CDMO corporations took her to senior global positions in the US and Germany. She has also been leading internationalization of mid-sized Life Science companies in Sweden and Germany, as well as building up Pharma technology licencing internationally. Recent years have given experience from CEO and Board positions in listed Swedish Life Science start-ups.
Previous roles: Previous to Ziccum, Ann was the CEO of SelectImmune Pharma AB, AcuCort AB and Monocl AB, as well as Head of the Inceptua CTS Business unit in Berlin, Germany and Licensing Director at Novozymes Biopharma in Copenhagen, Denmark. Furthermore, she held senior Global Business Development and Sales & Marketing Director roles in Cambrex Corp based in New Jersey, USA and Lanxess GmbH in Leverkusen, Germany. She has also been in Pharmaceutical manufacturing and Engineering management roles. Currently Ann holds a board position in Iconovo AB, after SenzaGen AB.
Ownership: 135 000 shares and 100 000 warrants.
Phone: +46 722 140 141
Johny Humaloja, CFO
Appointed: June 1, 2023.
Qualifications: MBA Business Administration and Management, Lund University (1992 – 1994). MSc. Business Administration and Economics, Lund University (1988 – 1992).
Experience: With decades of experience in biopharma, biotech and medtech, Johny Humaloja’s career is broad, deep and driven by a commitment to delivery and execution. He has held senior roles in Europe and the US including CFO, Financial and Logistics Director, Financial Control Director as well as Plant Controller (in the US) of a biotech manufacturing facility with an annual budget of 110 MUSD. He has led IPOs, change management & restructuring projects, global financial projects and legal structural change projects.
Previous roles: Prior to Ziccum, Johny was CFO for Amniotics AB where amongst other achievements he led the company through a successful IPO and listing on Nasdaq first north (in 2021). He has been the CFO of Genovis, the Nordic Finance and Logistics Director of Zambon Pharm (Nigaard Pharma), the Controller for the Nordics and Baltic of Boston Scientific, Financial Controller for Metso Minerals, Associate Director and Plant Controller for Biogen Idec and many more.
Appointed: Joined Ziccum August 2019, appointed Senior Formulation Specialist July 2020, appointed Scientific Director August 2022.
Qualifications: BSc in Pharmaceutical Development and Production at the Conservatoire National des Arts et Métiers Conservatoire, Paris. DEUST in Production and Quality in Pharmaceutical Industries, Formulation and Control quality, Aix-Marseille University, Marseille.
Experience: Fabrice is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years’ plus experience in formulation and drug delivery includes ten year’s lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens. Highly result-oriented, Fabrice’s extensive industry experience has been characterized by his determination, resourcefulness and commitment to solving new challenges with a creative and strategic mindset.
Previous roles: Fabrice has extensive industrial and academic experience in formulation. He was a Laboratory specialist at the University of Copenhagen’s Faculty of Health and Medical Sciences, designing and characterizing vaccine formulations. He was a scientist at SOLVE contract analytical lab (running specialized analytical instrumentation), he worked at Catalent (the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products) in formulation, preformulation and stability studies for oral dosage forms, as well as other roles throughout Europe.
Ownership: 1 000 shares and 19 182 warrants
Phone: +46 709 802 520